Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Moderna, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Moderna, Inc. (MRNA) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Moderna, Inc. (NASDAQ: MRNA).
On October 22, 2026, an early release of closely watched clinical trial results for Moderna and Merck’s joint experimental cancer vaccine appeared on the medical news website Oncology Central before being taken down shortly afterward. According to the briefly published report, combining the companies’ personalized mRNA cancer vaccine with Merck’s immunotherapy Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. Following this news, Moderna’s stock price dropped as much as $56.71 per share, or approximately 23.07%, during intraday trading on October 22, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Moderna, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Moderna, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Moderna, Inc. (MRNA) Investors Do?
How Did Moderna, Inc. (MRNA) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”